Početna › Crohnova bolest › Washington
Kliničke studije za Crohnova bolest u državi Washington
22 studija za Crohnova bolest traži sudionike na lokacijama u državi Washington.
Gradovi u državi Washington
Službeni tekst studije (engleski)
Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)
- Washington Gastroenterology - Tacoma ( Site 0295), Tacoma
U tijeku regrutacijaFaza 3
Sve dobne skupine · Oba spola · Ažurirano 2. lis 2026. · NCT06651281A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
- University of Washington ( Site 5115), Seattle
- Washington Gastroenterology - Tacoma ( Site 5004), Tacoma
U tijeku regrutacijaFaza 3
Od 16 do 80 godina · Oba spola · Ažurirano 2. lis 2026. · NCT06430801Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
- Washington Gastroenterology - Bellevue /ID# 283966, Bellevue
- Washington Gastroenterology - Tacoma /ID# 284143, Tacoma
- The Vancouver Clinic /ID# 280497, Vancouver
U tijeku regrutacijaFaza 2
Od 18 do 75 godina · Oba spola · Ažurirano 2. lis 2026. · NCT07697456A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
- GI Alliance, Bellevue
U tijeku regrutacijaFaza 4
Od 18 do 80 godina · Oba spola · Ažurirano 30. ruj 2026. · NCT06581328Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
- Virginia Mason Hospital and Medical Center /ID# 265574, Seattle
- Washington Gastroenterology - Tacoma /ID# 267302, Tacoma
U tijeku regrutacijaFaza 2
Od 18 do 75 godina · Oba spola · Ažurirano 25. ruj 2026. · NCT06548542A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
- GI Alliance Tacoma, Tacoma
U tijeku regrutacijaFaza 2/3
Od 18 godina i više · Oba spola · Ažurirano 25. ruj 2026. · NCT07196722A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
- University of Washington Medical Center, Seattle
U tijeku regrutacijaFaza 2
Od 18 do 75 godina · Oba spola · Ažurirano 25. ruj 2026. · NCT06233461Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- Washington Gastroenterology - Tacoma, Tacoma
U tijeku regrutacijaFaza 3
Od 18 do 70 godina · Oba spola · Ažurirano 24. ruj 2026. · NCT06937099An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- GI Alliance - Bellevue-Site Number: 8400143, Bellevue
- The Vancouver Clinic Inc. P.S.-Site Number: 8400090, Vancouver
U tijeku regrutacijaFaza 3
Od 16 do 80 godina · Oba spola · Ažurirano 23. ruj 2026. · NCT07184931A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- The Vancouver Clinic Inc. P.S.-Site Number: 8400090, Vancouver
U tijeku regrutacijaFaza 3
Od 16 do 80 godina · Oba spola · Ažurirano 23. ruj 2026. · NCT07184944A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
- Washington Gastroenterology- GIA, Tacoma
U tijeku regrutacijaFaza 4
Od 18 do 70 godina · Oba spola · Ažurirano 9. ruj 2026. · NCT06045754Familial Inflammatory Bowel Disease Early Risk
- Seattle Children's Hospital, Seattle
U tijeku regrutacijaOpažajna studijaZdravi dobrovoljci dobrodošli
Od 0 do 55 godina · Oba spola · Ažurirano 28. kol 2026. · NCT07791862A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
- GI Alliance Tacoma, Tacoma
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 28. kol 2026. · NCT07577843A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
- Seattle Children's Hospital, Seattle
U tijeku regrutacijaFaza 3
Od 2 do 17 godina · Oba spola · Ažurirano 24. kol 2026. · NCT05509777A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
- MultiCare Institute for Research & Innovation, Tacoma
U tijeku regrutacijaFaza 3
Od 2 do 17 godina · Oba spola · Ažurirano 3. kol 2026. · NCT06100289A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)
- Multicare Health System Institute for Research and Innovation, Tacoma
U tijeku regrutacijaFaza 3
Od 2 do 17 godina · Oba spola · Ažurirano 22. lip 2026. · NCT06405087Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease
- Seattle Children's Hospital, Seattle
U tijeku regrutacijaFaza 4
Od 6 do 17 godina · Oba spola · Ažurirano 27. svi 2026. · NCT05781152A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
- Swedish Cancer Institute, Seattle
- University of Washington Medical Center - Montlake, Seattle
U tijeku regrutacijaFaza 3
Od 18 do 65 godina · Oba spola · Ažurirano 27. svi 2026. · NCT06227910Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
- University of Washington, Seattle
U tijeku regrutacijaFaza 2
Od 18 do 75 godina · Oba spola · Ažurirano 27. tra 2026. · NCT06456593Seattle Spatial Transcriptomic Research in Inflammatory Bowel Disease Evaluation (STRIDE)
- Seattle Children's Hospital, Seattle
U tijeku regrutacijaOpažajna studija
Od 6 do 21 godina · Oba spola · Ažurirano 24. tra 2026. · NCT06315179A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
- Mirador Therapeutics Selected Site, Bellevue
- Mirador Therapeutics Selected Site, Silverdale
- Mirador Therapeutics Selected Site, Tacoma
U tijeku regrutacijaFaza 2
Od 18 do 80 godina · Oba spola · Ažurirano 12. ožu 2026. · NCT07113522Reverse-Engineering of Exclusive Enteral Nutrition (RE-EEN) in Crohn's Disease: A Multi-Center Trial
- Seattle Children's Hospital, Seattle
U tijeku regrutacija
Od 8 do 21 godina · Oba spola · Ažurirano 12. lip 2025. · NCT06216899Iz ClinicalTrials.gov, podaci preuzeti 5. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.